Primary squamous cell carcinoma of major salivary gland: "Sapienza Head and Neck Unit" clinical recommendations.
Primary squamous cell carcinoma
parotid gland
parotidectomy
salivary gland neoplasms
sialoadenectomy
submandibular gland
Journal
Rare tumors
ISSN: 2036-3605
Titre abrégé: Rare Tumors
Pays: England
ID NLM: 101526926
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
08
2020
accepted:
23
10
2020
entrez:
7
12
2020
pubmed:
8
12
2020
medline:
8
12
2020
Statut:
epublish
Résumé
Primary squamous cell carcinoma of salivary gland (SCG) is an extremely rare type of malignant salivary gland tumor, which in turn results in scarcity of data available regarding both its treatment and associated genetic alterations. A retrospective analysis of 12 patients with primary SCG was conducted, along with analysis of the association between treatment, clinical/pathological characteristics, and outcomes. Most patients (8) were staged IVa, with the majority of them (10) having G3 fast growing cancer. Local and systemic recurrence were reported in only three out of nine parotid cases (0 out of 2 submandibular SCGs). In two out of eight patients local relapse occurred after integrated treatment, while recurrence occurred in two out of three patients undergoing exclusive surgery. Five patients eventually died. Treatment of resectable disease must be aggressive and multimodal, with achievement of loco-regional control in order to reduce rate of recurrence and improve outcomes. Metastatic disease would require a therapeutic strategy tailored to the molecular profile in order to improve the currently disappointing results.
Identifiants
pubmed: 33282162
doi: 10.1177/2036361320973526
pii: 10.1177_2036361320973526
pmc: PMC7691911
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2036361320973526Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Conflict of interest: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: PAOLO MARCHETTI (PM) has/had a consultant/advisory role for BMS, RocheGenentech, MSD, Novartis, Amgen, Merck Serono, Pierre Fabre, Incyte. The other authors declare they have no competing interests.
Références
Crit Rev Oncol Hematol. 2017 Dec;120:93-97
pubmed: 29198342
Int J Cancer. 2006 Oct 15;119(8):1800-10
pubmed: 16721788
J Cancer Res Ther. 2015 Jul-Sep;11(3):664
pubmed: 26458694
CA Cancer J Clin. 2017 Mar;67(2):122-137
pubmed: 28128848
Head Neck. 2015 May;37(5):644-9
pubmed: 24585506
J Clin Oncol. 2007 Sep 1;25(25):3978-84
pubmed: 17761983
Cancer Treat Rev. 2018 Jan;62:50-60
pubmed: 29169144
Crit Rev Oncol Hematol. 2017 May;113:151-155
pubmed: 28427504
Ann Surg Oncol. 2016 Jun;23(6):2038-45
pubmed: 26790669
Head Neck. 2007 Oct;29(10):907-12
pubmed: 17563907
Head Neck. 2006 Jul;28(7):626-32
pubmed: 16475198
Arch Otolaryngol. 1984 Jan;110(1):45-9
pubmed: 6689907
Oral Oncol. 2007 Sep;43(8):729-34
pubmed: 17350323
J Clin Oncol. 2006 Jun 10;24(17):2673-8
pubmed: 16763282
J Dent Res. 2015 Nov;94(11):1516-23
pubmed: 26307039
Laryngoscope. 2001 Aug;111(8):1373-8
pubmed: 11568571
Cancer. 1990 Jun 1;65(11):2515-20
pubmed: 2337868
Cancer. 1991 Dec 1;68(11):2431-7
pubmed: 1933780
Head Neck. 2014 May;36(5):694-701
pubmed: 23606370
Oral Oncol. 2003 Oct;39(7):724-7
pubmed: 12907212
Head Neck Surg. 1987 Mar-Apr;9(4):235-40
pubmed: 3667298
J Clin Oncol. 2011 Jun 1;29(16):e473-6
pubmed: 21422415
Cancer. 1971 Jun;27(6):1415-8
pubmed: 4325986
Head Neck Surg. 1986 Nov-Dec;9(2):82-92
pubmed: 3623942
Ann Oncol. 2017 Sep 1;28(9):2206-2212
pubmed: 28911070
Ann Oncol. 2020 Mar;31(3):412-421
pubmed: 32067683
J Surg Oncol. 2016 Jul;114(1):36-43
pubmed: 27111278
Head Neck. 2017 Sep;39(9):1806-1818
pubmed: 28561907
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Oral Oncol. 2009 Jul;45(7):574-8
pubmed: 18804410
Cancer. 2016 Jun 15;122(12):1822-31
pubmed: 26928905
Oncologist. 2013;18(3):294-300
pubmed: 23429737
Arch Otolaryngol Head Neck Surg. 1992 Aug;118(8):798-801
pubmed: 1642829
Am J Surg Pathol. 2000 Apr;24(4):579-86
pubmed: 10757407
Head Neck. 2004 Aug;26(8):681-92; discussion 692-3
pubmed: 15287035
Eur J Cancer B Oral Oncol. 1996 Jul;32B(4):251-9
pubmed: 8776422
J Pathol. 1985 May;146(1):51-8
pubmed: 4009321
Curr Med Chem Anticancer Agents. 2004 Nov;4(6):543-51
pubmed: 15579019
Arch Otolaryngol. 1976 Jun;102(6):355-7
pubmed: 1275803
Arch Otolaryngol Head Neck Surg. 1991 Mar;117(3):307-15
pubmed: 1998571
Oncotarget. 2015 Jul 20;6(20):18224-37
pubmed: 26053092
Plast Reconstr Surg. 1987 Apr;79(4):550-4
pubmed: 3823246
Oncotarget. 2017 Jul 5;8(46):80416-80428
pubmed: 29113313
EMBO J. 2013 Jul 17;32(14):1977-89
pubmed: 23736260
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2899-906
pubmed: 19861510
Cancer Control. 2016 Jul;23(3):242-8
pubmed: 27556664
Ann Diagn Pathol. 2014 Feb;18(1):10-3
pubmed: 24238845
Am J Clin Oncol. 2018 Nov;41(11):1083-1088
pubmed: 29462123
Appl Immunohistochem Mol Morphol. 2015 Mar;23(3):172-7
pubmed: 24710085
Crit Rev Oncog. 2018;23(3-4):139-151
pubmed: 30311570
J Laryngol Otol. 2009 Feb;123(2):250-2
pubmed: 18405406
Nat Genet. 2003 Feb;33(2):208-13
pubmed: 12539049
Cancers (Basel). 2019 Jan 27;11(2):
pubmed: 30691222
Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1193-7
pubmed: 14623749